OverviewChartNewsTraderScreen

Citi Discount Zert 4AB 25.09.2024/  DE000KJ4JJE2  /

Frankfurt Zert./CITI
2024-04-09  9:24:03 AM Chg.+0.490 Bid2:24:31 PM Ask- Underlying Strike price Expiration date Option type
149.220EUR +0.33% -
Bid Size: -		 -
Ask Size: -		 ABBVIE INC. D... - - 2024-09-25 Call
GlobeNewswire 05-01 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire 04-30 CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings,...
GlobeNewswire 04-30 U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire 04-25 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
GlobeNewswire 04-25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire 04-24 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire 04-23 Leaders from Fortune 100 Best Companies to Work For To Share Insights at For All Summit May 7-9
GlobeNewswire 04-22 TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire 04-22 Anthos Therapeutics Announces Appointment of Bill Meury as CEO
GlobeNewswire 04-19 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes a...
GlobeNewswire 04-19 Life Science Cares Launches in Switzerland
GlobeNewswire 04-19 Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
GlobeNewswire 04-19 Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...
GlobeNewswire 04-18 Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial fo...
GlobeNewswire 04-17 Royalty Pharma Declares Second Quarter 2024 Dividend
GlobeNewswire 04-16 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
GlobeNewswire 04-16 OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of C...
GlobeNewswire 04-16 Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire 04-15 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...
Newsfile Corp 04-12 Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Acce...
GlobeNewswire 04-09 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, ...
GlobeNewswire 04-09 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
GlobeNewswire 04-08 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...
GlobeNewswire 04-08 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...
GlobeNewswire 04-06 Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...